BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (September 2014)

24 slides from BioSpecifics Technologies's investor presentation, Sep 11, 2014

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    ° \4 Innovators in the development & commercialization of ‘INJECTABLE COLLAGENASE i, . BioSpecifics September 2014

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: Corporate Overview

    Corporate Overview BioSpecifics is a profitable, commercial-stage biopharma company maximizing the potential of injectable collagenase for multiple indications XIAFLEX® (collagenase clostridium histolyticum or CCH) is now marketed for Dupuytren’s contracture and Peyronie’s disease in the U.S. by str

  4. Slide 4: Vast Therapeutic Potential of CCH

    Vast Therapeutic Potential of CCH CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications: Dupuytren’s contracture’ Froze

  5. Slide 5: Approved Indications for XIAFLEX

    Approved Indications for XIAFLEX Marketed ,, Dupuytren’s Multi-cord sBLA PDUFA date is October 20, 2014 Contracture ert we Potential decision in late 1Q15 on MAA filed by Sobi Disease Source: Auxilium Pharmaceuticals, Inc.

  6. Slide 6: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand Definition and One or more fingers caused to contract toward the palm Key Complications Limits range of motion of the fingers often resulting in physical disability and impaired quality of life First and Only Approved in th

  7. Slide 7: Label Expansion Opportunity

    Label Expansion Opportunity » SDI Health LLC estimates 35 to 40% of annual Dupuytren’s contracture surgeries in U.S. are performed to treat two or Pre-treatment: more cords concurrently ‘ PDUFA date: October 20, 2014 ~ FDA to decide on sBLA, submitted by Auxilium, for XIAFLEX label expansion to allo

  8. Slide 8: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Excess of inelastic collagen causing penile curvature deformity Definition & Results in pain with erection, penile shortening, indentations, erectile Key Complications dysfunction and/or difficulty with sexual intercourse Potential loss of self-esteem and depression fo

  9. Slide 9: Launch Progress — Sales Up 75% in 2Q14 vs. 2Q13

    Launch Progress — Sales Up 75% in 2Q14 vs. 2Q13 Focused, disciplined initial product rollout 5,000-6,500 patients receive invasive treatment for Peyronie’s disease each year (plication, grafting, prosthesis surgery or verapamil injections) ~400 urologists account for 90% of PD surgeries REMS certifi

  10. Slide 10: Launch Progress Cont.

    Launch Progress Cont. Reimbursement approval by payers (Auxilium Advantage) All eight Medicare beneficiaries confirmed coverage at policy level; 29 major commercial health plans have approved patients for treatment Listed as 'medically necessary’ in Clinical Policy Bulletin, when administered under

  11. Slide 11: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs frozen Top-line data in 1015 Shoulder ae ci Lipoma *) Human Complete enrollment in Phase 2 trial in 1Q15 Lipoma Cellulite Initiation of Phase 2b trial in 2Q15 *Uterine Fibroids *BioSpecifics-managed development program

  12. Slide 12: CCH for Canine and Human Lipomas

    CCH for Canine and Human Lipomas BioSpecifics-Managed Programs Encapsulated deposits of benign fatty tumors Definition and : Detected as bulges under the skin that occur in both humans and dogs Key Complications Can be serious health problem in dogs, restricting motion in older dogs Potential to be

  13. Slide 13: Chien-804 Placebo-Controlled Phase 2 Trial in Canines

    Chien-804 Placebo-Controlled Phase 2 Trial in Canines BioSpecifics reported data from placebo-controlled, randomized Phase 2 trial for CCH in canines with benign subcutaneous lipomas Study did not meet primary endpoint but demonstrated benefit in secondary measures: Responder analysis: » Visible sur

  14. Slide 14: Dose Escalation Phase 2 Clinical Trial in Humans

    Dose Escalation Phase 2 Clinical Trial in Humans BioSpecifics reported data from open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combinin

  15. Slide 15: CCH for Uterine Fibroids

    CCH for Uterine Fibroids Study Results Expected in 4Q14 Benign tumors with significant co- Definition & morbidlees Pain, decreased fertility, miscarriage, Key Complications heavy menstrual bleeding and frequent urination Potential to be Primary indication for hysterectomy in . U.S., accounting for b

  16. Slide 16: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Top-line Data from Phase 2b Study Expected in 1Q15 Inflammation and thickening of ta shoulder capsule due to collagen Definition and Secretion Key Complications Limits the range of motion of the shoulder and painful Potential to be Common available treatment option i

  17. Slide 17: Statistically Significant CCH Dose Response in Phase 2a Study

    Statistically Significant CCH Dose Response in Phase 2a Study 60 + 1 Statistically significant improvements in H <0.05 Compari onward Flexion both the 0.58 mg(1mL) and 0.58 550 | to Exorcion: Cobar =F) shctaierAbsuciOn mg(2mL) cohorts over baseline scores 3 ©) External Rotation vs. the exercise-only

  18. Slide 18: CCH for Cellulite

    CCH for Cellulite Phase 2a Study Results Reported in 3Q14 Skin dimpling as a result of collagen fibrous septae held in an irregular pattern Definition under the skin, occurring mainly on the buttocks, lower limbs, and abdomen Significant Market Affects 85-98% of women (est.) and rarely in men Opport

  19. Slide 19: CCH for Cellulite

    CCH for Cellulite Initiation of Phase 2b Study Expected in 2Q15 Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with trea

  20. Slide 20: Auxilium Partnership for Development and Commercialization of CCH

    Auxilium Partnership for Development and Commercialization of CCH >$45.1M Received Over $45M total received in licensing, sublicensing, milestone, COGS, and from Auxilium royalty payments as of June 30, 2014 Frrcre Payments Low double digit royalties as % of net sales by Auxilium Additional mark coG

  21. Slide 21: Corporate Highlights

    Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: » Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in U.S. until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 Peyronie’s Disease: Aux

  22. Slide 22: Consistently Profitable Annually

    Consistently Profitable Annually 2Q14 Financial Highlights For the quarter For the year ended ended 06/30/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments $ 16,633,708 $ 12,591,825 Income Statement Revenues $ 2,652,505, $ 14,467,240 Other income 7,352 26,202 Costs and

  23. Slide 23: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Steady Momentum in BioSpecifics-Managed Indications Upcoming Milestones *Human Lipomas Ocomplete enrollment in Phase 2 placebo-controlled opt-in trial in 1Q15 waar rae . (120 day opt-in period for Auxilium to license rights ends in 4Q14 ene Q Report pre-clinical study

  24. Slide 24: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercializationof | Qs ECTABLE = (fe COLLAGEN Gail BioSpecifics ———septenbersox TECHNOLOGIES CORP.

Biospecifics Technologies — Investor Presentation (September 2014) on 6ix